The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Open accessAbstract
Purpose: This randomized, controlled, multicenter, open-label, phase III study compared docetaxel versus paclitaxel in patients with advanced breast cancer that had progressed after an anthracycline-containing chemotherapy regimen. Patients and Methods: Patients (n = 449) were randomly assigned to receive either docetaxel 100 mg/m 2 (n = 225) or paclitaxel 175 mg/m 2 (n = 224) on day 1, every 21 days until tumor progression, unacceptable toxicity, or withdrawal of consent. Results: In the intent-to-treat population, both the median overall survival (OS, 15.4 v 12.7 months; hazard ratio [HR], 1.41; 95% CI, 1.15 to 1.73; P = .03) and the median time to progression (TTP, 5.7 months v 3.6 months; HR, 1.64; 95% CI, 1.33 to 2.02; P < .0001) for docetaxel were significantly longer than for paclitaxel, and the overall response rate (ORR, 32% v 25%; P = .10) was higher for docetaxel. These results were confirmed by multivariate analyses. The incidence of treatment-related hematologic and nonhematologic toxicities was greater for docetaxel than for paclitaxel; however, quality-of-life scores were not statistically different between treatment groups over time. Conclusion: Docetaxel was superior to paclitaxel in terms of OS and TTP. ORR was higher for docetaxel. Hematologic and nonhematologic toxicities occurred more frequently in the docetaxel group. The global quality-of-life scores were similar for both agents over time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,845
Arky, R. A. (1994) · Cited by 2,632
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,081
Self-citationSledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., & Wood, W. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.013 · Cited by 707
Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol
Ringel, I., & Horwitz, S. B. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.4.288 · Cited by 677
Chan, S., Friedrichs, K., Noel, D., Pintér, T., Van Belle, S., Vorobiof, D., Duarte, R., Gil Gil, M., Bodrogi, I., Murray, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2341 · Cited by 641
Bcl2 is the guardian of microtubule integrity.
Haldar, S., Basu, A., & Croce, C. M. (1997) · PubMed · Cited by 599
Cited by
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Extending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson, H. G., Bao, Y., Shah, M. A., Paulk, M. E., LeBlanc, T. W., Schneider, B. J., Garrido, M. M., Reid, M. C., Berlin, D. A., Adelson, K. B., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2378 · Cited by 645
Roché, H., Fumoleau, P., Spielmann, M., Canon, J.-L., Delozier, T., Serin, D., Symann, M., Kerbrat, P., Soulié, P., Eichler, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3916 · Cited by 577
Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5391 · Cited by 538
Self-citationHugh, J., Hanson, J., Cheang, M. C. U., Nielsen, T. O., Perou, C. M., Dumontet, C., Reed, J., Krajewska, M., Treilleux, I., Rupin, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1024 · Cited by 526
nab-Paclitaxel mechanisms of action and delivery
Yardley, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.041 · Cited by 508
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472
Chia, S. K., Speers, C. H., D'yachkova, Y., Kang, A., Malfair‐Taylor, S., Barnett, J., Coldman, A., Gelmon, K. A., O'Reilly, S. E., & Olivotto, I. A. (2007) · Cancer · doi:10.1002/cncr.22867 · Cited by 465
Albain, K. S., Nag, S. M., Calderillo-Ruiz, G., Jordaan, J. P., Llombart, A. C., Pluzanska, A., Rolski, J., Melemed, A. S., Reyes-Vidal, J. M., Sekhon, J. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9362 · Cited by 425
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Progress in adjuvant chemotherapy for breast cancer: an overview
Anampa, J., Makower, D., & Sparano, J. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0439-8 · Cited by 373
Health state utilities for metastatic breast cancer
Lloyd, A., Nafees, B., Narewska, J., Dewilde, S., & Watkins, J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603326 · Cited by 354
Kerckhove, N., Collin, A., Condé, S., Chaleteix, C., Pezet, D., & Balayssac, D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00086 · Cited by 350
Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5397 · Cited by 341
Therapeutic strategies in epithelial ovarian cancer
Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-14 · Cited by 319
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., & Kurian, A. W. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky062 · Cited by 315
Feng, S.-S., Mei, L., Anitha, P., Gan, C. W., & Zhou, W. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.045 · Cited by 306
Thomas, E., Tabernero, J., Fornier, M., Conté, P., Fumoleau, P., Lluch, A., Vahdat, L. T., Bunnell, C. A., Burris, H. A., Viens, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9102 · Cited by 290
Third consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
Colevas, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3348 · Cited by 257
Dermatological adverse events with taxane chemotherapy
Sibaud, V., Lebœuf, N. R., Roche, H., Belum, V. R., Gladieff, L., Deslandres, M., Montastruc, M., Eche, A., Vigarios, E., Dalenc, F., et al. (2016) · European Journal of Dermatology · doi:10.1684/ejd.2016.2833 · Cited by 257
NCCN Task Force Report: Management of Neuropathy in Cancer
Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E., Ho, M., Junck, L., Morris, G. S., Paice, J. A., Tummala, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0078 · Cited by 257
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Rivera, E., & Cianfrocca, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2607-5 · Cited by 159
Therapy-Induced Senescence Drives Bone Loss
Yao, Z., Murali, B., Ren, Q., Luo, X., Faget, D. V., Cole, T., Ricci, B., Thotala, D., Monahan, J., van Deursen, J. M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2348 · Cited by 129
Clinical development of novel proteasome inhibitors for cancer treatment
Yang, H., Zonder, J. A., & Dou, Q. P. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903002074 · Cited by 85
Therapeutic options for metastatic breast cancer
Morris, P. G., McArthur, H. L., & Hudis, C. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902834961 · Cited by 59
Alendronate-modified polymeric micelles for the treatment of breast cancer bone metastasis
Liu, T., Romanova, S., Wang, S., Hyun, M. A., Zhang, C., Cohen, S. M., Singh, R. K., & Bronich, T. K. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01343 · Cited by 34
Metadata
- Authors
- Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., Mennel, R., Richards, D., Olsen, S., Meyers, M. L., & Ravdin, P. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-20
- Volume
- 23
- Issue
- 24
- Pages
- 5542-5551
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2128941584
- Cited by
- 547
- References
- 29
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.